Compare GRFS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | DNTH |
|---|---|---|
| Founded | 1940 | 2015 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.1B |
| IPO Year | N/A | 2018 |
| Metric | GRFS | DNTH |
|---|---|---|
| Price | $8.48 | $92.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $10.15 | ★ $121.00 |
| AVG Volume (30 Days) | 649.3K | ★ 858.8K |
| Earning Date | 07-28-2022 | 05-11-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $4.69 | N/A |
| Revenue Next Year | $6.49 | $29.48 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.90 | $16.77 |
| 52 Week High | $11.14 | $96.50 |
| Indicator | GRFS | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 67.84 |
| Support Level | $8.27 | $33.94 |
| Resistance Level | $9.08 | N/A |
| Average True Range (ATR) | 0.21 | 4.33 |
| MACD | 0.09 | -0.24 |
| Stochastic Oscillator | 67.73 | 79.15 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.